Patient Death in Erasca Trial Sparks Securities Fraud Suit at $2.8B Cost

For healthcare compliance officers and clinical researchers, the Erasca case raises critical questions about when a single adverse event becomes material to investors. The death of a patient just one month after receiving ERAS-0015, combined with alleged undisclosed intellectual property issues, highlights how patient safety disclosures—or lack thereof—can trigger both regulatory scrutiny and massive shareholder losses in the biotech sector.

Erasca, Inc. (NASDAQ: ERAS) faces a securities class action lawsuit that crystallizes the high-stakes intersection of drug development, intellectual property, and investor disclosure. Filed by Hagens Berman, the suit seeks to represent investors who purchased Erasca stock between January 14, 2025 and April 26, 2026, after shares plummeted $9.25 — a 48% single-day decline — erasing $2.8 billion in market capitalization. The complaint, brought under the federal securities laws, alleges that Erasca knowingly or recklessly misled the market concerning its lead cancer candidate, ERAS-0015, an investigational pan-RAS molecular glue targeting solid tumors like pancreatic ductal adenocarcinoma.

“

Filed by Hagens Berman, the suit seeks to represent investors who purchased Erasca stock between January 14, 2025 and April 26, 2026, after shares plummeted $9.25 — a 48% single-day decline — erasing $2.8 billion in market capitalization.

The core of the allegations turns on two revelations that surfaced around April 26, 2026. First, Revolution Medicines (RevMed) — a direct competitor — accused Erasca of patent infringement concerning ERAS-0015, throwing the company’s intellectual property exclusivity into doubt. Second, a patient enrolled in a clinical trial of ERAS-0015 died approximately one month after receiving the drug, a fact that had not been disclosed to investors despite Erasca’s ongoing positive framing.

The complaint states that as recently as March 12, 2026, Erasca publicly touted its IP protections, citing a patent family licensed from Joyo that includes one issued U.S. patent, one pending U.S. non-provisional application, one issued foreign patent, and thirteen pending foreign patent applications. It also contends that the company favorably compared its 40‑milligram dose cohort of ERAS-0015 to RevMed’s 400‑milligram dose of RMC-6236, implying comparable efficacy and safety. The lawsuit alleges these comparisons were scientifically improper, lacked a reasonable basis, and exposed the company to significant infringement risk — facts unknown to investors when the statements were made.

The securities fraud theory is classic: positive statements about a drug’s prospects and IP strength artificially inflated Erasca’s stock price during the class period; when corrective disclosures revealed the alleged truth — the patient death and the patent infringement claim — the price collapsed. As a result, investors who purchased shares at inflated prices suffered losses. The lawsuit seeks to recover damages under Section 10(b) and Rule 10b‑5 of the Securities Exchange Act, as well as control person liability under Section 20(a).

For the biotech sector, this action is a stark reminder of the regulatory and litigation risks inherent in pre‑revenue drug development. Investor disclosures by such companies are heavily scrutinized because stock valuations are closely tied to clinical milestones and IP strength. A single adverse event or competitor challenge can trigger catastrophic investor re‑pricing. The case also underscores the challenges for plaintiffs in proving scienter — the mental state requirement — in the biotech context. Erasca will likely argue that forward‑looking statements were accompanied by cautionary language, that the IP dispute is a typical competitive risk, and that the patient death was not material because ERAS-0015 is still in early‑stage development. However, the complaint’s specificity — citing internal comparisons and the timing of disclosure — may give plaintiffs a basis to plead a strong inference of fraudulent intent.